Quick Answer
TScan Therapeutics, Inc. reported Long Term Debt of $32.53 million for the year ending 2025.
- TScan Therapeutics, Inc. showed an increase of +1.4% in Long Term Debt from 2024 to 2025.
- This data is from TScan Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2022: $29.07 million | Q1 2023: $29.50 million | Q2 2023: $29.72 million | Q3 2023: $28.84 million | Q1 2024: $23.45 million | Q2 2024: $20.11 million | Q3 2024: $30.65 million | Q1 2025: $32.18 million | Q2 2025: $32.30 million | Q3 2025: $32.41 million.
- Over the full 4 years of available data (2022 to 2025), TScan Therapeutics, Inc.'s Long Term Debt has grown by 11.1%.
- Historical annual values: Fiscal year 2025: $32.53 million | Fiscal year 2024: $32.07 million | Fiscal year 2023: $26.70 million | Fiscal year 2022: $29.29 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: